| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7390091 | Value in Health Regional Issues | 2016 | 6 Pages |
Abstract
Ticagrelor is more cost-effective than prasugrel in reducing all-cause mortality in patients with ACS. The cost-effectiveness of ticagrelor and prasugrel become similar, however, when accounting for the impact of dyspnea on QALY.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Ying Jiao PhD, Ai Leng PhD, Liang MSc (iHTA), Monica MHSc, Tuck Seng MHSM, Mark Y. MBBS, MHS, Boon Peng BPharm,